| Factor Information | |
|---|---|
| Data ID | 338 |
| Factor | antenatal detection |
| Description | N/A |
| Biomarker | NA |
| Classification | A2 (clinical factor - diagnosis) |
| Association | |
|---|---|
| Application | diagnosis |
| Objective | neonate with CHD |
| p Value | 0.05 |
| Conclusion | Antenatal detection increased from 32% in the first 3 years to 47% in the last 3 years. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 440 |
| CHD Type | non-isolated CHD |
| CHD Subtype | D-TGA, IVS/D-TGA, VSD/AAO, IVS/AAO, VSD |
| Reference | |
|---|---|
| PMID | 30292491 |
| Year | 2019 |
| Title | Antenatal Detection of Treatable Critical Congenital Heart Disease Is Associated with Lower Morbidity and Mortality |
| Sample | ||
|---|---|---|
| Population | infant | |
| Source | data | |
| Region | New Zealand, Auckland | |
| Method | a population-based study | |
| Race | New Zealander | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | period of 2006-2008(Treatment) | period of 2012-2014(Control) |
| Number | 25(total:79) | 41(total:88) |
| Age | 39 weeks (35-42) | 39 weeks (35-42) |
| Gender (Male: Female) | N/A | N/A |
| Marker Level | 0.32 | 0.47 |
